SPARC.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally...

Stats
Dagens volum	4.76M
Gjennomsnittsvolum	511 527
Markedsverdi	79.35B
EPS	INR0 ( 2024-02-04 )
Neste inntjeningsdato	( INR0 ) 2024-05-19
Last Dividend	INR0 ( N/A )
Next Dividend	INR0 ( N/A )
P/E	-21.60
ATR14	INR0 (0.00%)

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: 0.00 (neutral)

Signal:(0) Neutral

Sun Pharma Advanced Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sun Pharma Advanced Korrelasjon - Valuta/Råvare

0.00
( neutral )

Sun Pharma Advanced Økonomi

Annual	2022
Omsetning:	INR2.31B
Bruttogevinst:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Omsetning:	INR2.31B
Bruttogevinst:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Omsetning:	INR1.37B
Bruttogevinst:	INR105.52M (7.69 %)
EPS:	INR-8.24

FY	2021
Omsetning:	INR2.53B
Bruttogevinst:	INR465.55M (18.40 %)
EPS:	INR-5.77

Financial Reports:

No articles found.

Sun Pharma Advanced

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited